| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Delivery Systems | 112 | 2024 | 250 | 13.520 |
Why?
|
| Nanoparticles | 36 | 2024 | 104 | 6.610 |
Why?
|
| Polymers | 62 | 2024 | 133 | 5.250 |
Why?
|
| Tissue Engineering | 23 | 2023 | 52 | 5.130 |
Why?
|
| Drug Carriers | 44 | 2024 | 93 | 5.120 |
Why?
|
| Biocompatible Materials | 29 | 2024 | 60 | 4.190 |
Why?
|
| Animals | 97 | 2024 | 1063 | 4.180 |
Why?
|
| Chitosan | 19 | 2023 | 46 | 3.660 |
Why?
|
| Hydrogels | 19 | 2023 | 42 | 3.300 |
Why?
|
| Pharmaceutical Preparations | 20 | 2024 | 44 | 3.080 |
Why?
|
| Regenerative Medicine | 6 | 2023 | 9 | 2.730 |
Why?
|
| Tissue Scaffolds | 18 | 2024 | 45 | 2.650 |
Why?
|
| Humans | 130 | 2024 | 14077 | 2.580 |
Why?
|
| Nanotubes, Carbon | 5 | 2023 | 9 | 2.490 |
Why?
|
| Delayed-Action Preparations | 29 | 2019 | 68 | 2.460 |
Why?
|
| Alginates | 15 | 2024 | 32 | 2.360 |
Why?
|
| Printing, Three-Dimensional | 11 | 2023 | 21 | 2.240 |
Why?
|
| Nanofibers | 6 | 2024 | 13 | 2.060 |
Why?
|
| Lactic Acid | 10 | 2014 | 33 | 1.780 |
Why?
|
| Wound Healing | 8 | 2024 | 24 | 1.760 |
Why?
|
| Polyglycolic Acid | 9 | 2014 | 16 | 1.710 |
Why?
|
| Nanomedicine | 10 | 2022 | 23 | 1.690 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 8 | 1.630 |
Why?
|
| Tablets | 18 | 2019 | 39 | 1.590 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 31 | 1.590 |
Why?
|
| Nanotechnology | 13 | 2022 | 28 | 1.580 |
Why?
|
| Praziquantel | 2 | 2022 | 5 | 1.570 |
Why?
|
| Mice | 14 | 2024 | 134 | 1.510 |
Why?
|
| Chemistry, Pharmaceutical | 32 | 2017 | 76 | 1.500 |
Why?
|
| Polymethacrylic Acids | 7 | 2024 | 14 | 1.470 |
Why?
|
| Technology, Pharmaceutical | 16 | 2022 | 35 | 1.440 |
Why?
|
| Ovarian Neoplasms | 6 | 2020 | 15 | 1.440 |
Why?
|
| Drug Compounding | 12 | 2016 | 22 | 1.430 |
Why?
|
| Neurodegenerative Diseases | 5 | 2016 | 19 | 1.400 |
Why?
|
| Tuberculosis | 3 | 2023 | 530 | 1.390 |
Why?
|
| Nerve Regeneration | 8 | 2021 | 22 | 1.380 |
Why?
|
| Patents as Topic | 9 | 2021 | 18 | 1.350 |
Why?
|
| Cross-Linking Reagents | 15 | 2021 | 33 | 1.300 |
Why?
|
| Nanospheres | 4 | 2023 | 13 | 1.260 |
Why?
|
| Polyethylene Glycols | 15 | 2021 | 48 | 1.230 |
Why?
|
| Biological Availability | 18 | 2021 | 43 | 1.230 |
Why?
|
| Blood-Brain Barrier | 8 | 2023 | 23 | 1.200 |
Why?
|
| Antineoplastic Agents | 11 | 2022 | 61 | 1.200 |
Why?
|
| Particle Size | 24 | 2022 | 72 | 1.180 |
Why?
|
| Polysaccharides, Bacterial | 5 | 2021 | 35 | 1.170 |
Why?
|
| Nanostructures | 13 | 2021 | 40 | 1.140 |
Why?
|
| Lipopolysaccharides | 3 | 2023 | 37 | 1.130 |
Why?
|
| Parkinson Disease | 8 | 2016 | 19 | 1.120 |
Why?
|
| Neurons | 8 | 2021 | 23 | 1.100 |
Why?
|
| Curcumin | 4 | 2020 | 13 | 1.040 |
Why?
|
| Neoplasms | 4 | 2023 | 141 | 1.040 |
Why?
|
| Ganciclovir | 5 | 2015 | 12 | 1.030 |
Why?
|
| Models, Molecular | 16 | 2018 | 84 | 1.010 |
Why?
|
| Nerve Tissue | 3 | 2022 | 7 | 1.000 |
Why?
|
| Rats | 15 | 2024 | 130 | 0.980 |
Why?
|
| Vaccines | 2 | 2023 | 84 | 0.970 |
Why?
|
| Administration, Oral | 22 | 2021 | 113 | 0.960 |
Why?
|
| Cellulose | 9 | 2017 | 21 | 0.940 |
Why?
|
| Osteoarthritis | 1 | 2024 | 4 | 0.920 |
Why?
|
| Theranostic Nanomedicine | 3 | 2020 | 6 | 0.910 |
Why?
|
| Antiviral Agents | 4 | 2018 | 107 | 0.910 |
Why?
|
| Drug Liberation | 23 | 2019 | 52 | 0.900 |
Why?
|
| Bandages | 7 | 2023 | 19 | 0.900 |
Why?
|
| Peripheral Nerve Injuries | 2 | 2021 | 4 | 0.900 |
Why?
|
| Liposomes | 11 | 2022 | 33 | 0.900 |
Why?
|
| Lung | 1 | 2024 | 70 | 0.900 |
Why?
|
| Magnetite Nanoparticles | 2 | 2021 | 4 | 0.890 |
Why?
|
| Peptides | 7 | 2023 | 40 | 0.890 |
Why?
|
| Hydrogen-Ion Concentration | 21 | 2020 | 61 | 0.890 |
Why?
|
| Bioprinting | 6 | 2021 | 13 | 0.890 |
Why?
|
| Estrogens | 1 | 2023 | 6 | 0.860 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2023 | 10 | 0.840 |
Why?
|
| Ionic Liquids | 1 | 2022 | 1 | 0.840 |
Why?
|
| Menopause | 1 | 2023 | 24 | 0.840 |
Why?
|
| Polypharmacy | 1 | 2022 | 5 | 0.830 |
Why?
|
| Isoniazid | 6 | 2023 | 110 | 0.790 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2024 | 158 | 0.780 |
Why?
|
| Sciatic Nerve | 1 | 2021 | 2 | 0.780 |
Why?
|
| Polysaccharides | 6 | 2024 | 45 | 0.780 |
Why?
|
| Macromolecular Substances | 2 | 2021 | 5 | 0.780 |
Why?
|
| Proteins | 6 | 2021 | 20 | 0.770 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2023 | 113 | 0.760 |
Why?
|
| Rifampin | 5 | 2023 | 189 | 0.750 |
Why?
|
| Schistosomiasis | 1 | 2021 | 8 | 0.750 |
Why?
|
| Anthelmintics | 1 | 2021 | 9 | 0.750 |
Why?
|
| Swine | 22 | 2019 | 49 | 0.750 |
Why?
|
| Porosity | 12 | 2018 | 24 | 0.730 |
Why?
|
| Solubility | 20 | 2017 | 51 | 0.730 |
Why?
|
| Naphthoquinones | 1 | 2020 | 3 | 0.720 |
Why?
|
| Cell Line, Tumor | 10 | 2024 | 70 | 0.720 |
Why?
|
| Pectins | 7 | 2016 | 14 | 0.710 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 6 | 2018 | 17 | 0.700 |
Why?
|
| Gels | 8 | 2023 | 17 | 0.700 |
Why?
|
| Polyesters | 7 | 2023 | 16 | 0.690 |
Why?
|
| Surface Properties | 19 | 2020 | 46 | 0.690 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 17 | 2023 | 44 | 0.680 |
Why?
|
| Levodopa | 7 | 2015 | 20 | 0.680 |
Why?
|
| Zidovudine | 7 | 2017 | 59 | 0.670 |
Why?
|
| Anti-HIV Agents | 10 | 2019 | 1275 | 0.670 |
Why?
|
| Anti-Bacterial Agents | 7 | 2023 | 274 | 0.670 |
Why?
|
| Mouth Mucosa | 4 | 2015 | 7 | 0.670 |
Why?
|
| Cell Line | 3 | 2021 | 92 | 0.660 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2023 | 326 | 0.650 |
Why?
|
| Models, Chemical | 6 | 2014 | 13 | 0.630 |
Why?
|
| Administration, Buccal | 5 | 2015 | 7 | 0.620 |
Why?
|
| Computer-Aided Design | 2 | 2016 | 6 | 0.610 |
Why?
|
| Female | 22 | 2024 | 8751 | 0.600 |
Why?
|
| Antitubercular Agents | 4 | 2023 | 299 | 0.600 |
Why?
|
| Oils, Volatile | 2 | 2023 | 10 | 0.570 |
Why?
|
| Aqueous Humor | 2 | 2007 | 5 | 0.560 |
Why?
|
| Neuroprotective Agents | 5 | 2018 | 15 | 0.560 |
Why?
|
| Tankyrases | 3 | 2022 | 4 | 0.560 |
Why?
|
| Excipients | 8 | 2023 | 13 | 0.550 |
Why?
|
| Drug Design | 9 | 2017 | 28 | 0.550 |
Why?
|
| Adhesives | 3 | 2011 | 5 | 0.540 |
Why?
|
| Polyvinyl Alcohol | 7 | 2016 | 16 | 0.530 |
Why?
|
| Kinetics | 13 | 2017 | 65 | 0.530 |
Why?
|
| Industry | 1 | 2016 | 6 | 0.520 |
Why?
|
| Posterior Eye Segment | 2 | 2018 | 4 | 0.520 |
Why?
|
| HIV Infections | 8 | 2024 | 4946 | 0.520 |
Why?
|
| Enzyme Inhibitors | 4 | 2020 | 22 | 0.520 |
Why?
|
| Eye Diseases | 3 | 2016 | 7 | 0.510 |
Why?
|
| Probiotics | 4 | 2016 | 12 | 0.500 |
Why?
|
| Rabbits | 9 | 2023 | 35 | 0.500 |
Why?
|
| Acrylic Resins | 8 | 2017 | 17 | 0.500 |
Why?
|
| Antiparkinson Agents | 5 | 2018 | 15 | 0.500 |
Why?
|
| Nicotine | 3 | 2011 | 12 | 0.490 |
Why?
|
| Hyaluronic Acid | 4 | 2024 | 9 | 0.490 |
Why?
|
| Brain | 7 | 2022 | 53 | 0.470 |
Why?
|
| Phenytoin | 2 | 2015 | 4 | 0.470 |
Why?
|
| Micelles | 4 | 2022 | 6 | 0.460 |
Why?
|
| Computer Simulation | 14 | 2016 | 53 | 0.460 |
Why?
|
| Intellectual Property | 2 | 2015 | 3 | 0.460 |
Why?
|
| Copper | 5 | 2024 | 15 | 0.460 |
Why?
|
| Vagina | 6 | 2023 | 91 | 0.460 |
Why?
|
| Lipids | 4 | 2022 | 81 | 0.450 |
Why?
|
| Anti-Infective Agents | 3 | 2013 | 56 | 0.450 |
Why?
|
| Temperature | 10 | 2021 | 56 | 0.450 |
Why?
|
| Polyelectrolytes | 3 | 2019 | 6 | 0.430 |
Why?
|
| Fibroblasts | 3 | 2023 | 14 | 0.430 |
Why?
|
| Hexuronic Acids | 9 | 2017 | 19 | 0.430 |
Why?
|
| Glucuronic Acid | 9 | 2017 | 19 | 0.430 |
Why?
|
| Indomethacin | 6 | 2015 | 17 | 0.430 |
Why?
|
| Microscopy, Electron, Scanning | 10 | 2020 | 34 | 0.420 |
Why?
|
| Administration, Intravaginal | 9 | 2023 | 50 | 0.420 |
Why?
|
| Rats, Sprague-Dawley | 7 | 2021 | 63 | 0.420 |
Why?
|
| Extracellular Matrix | 3 | 2022 | 13 | 0.420 |
Why?
|
| Rheology | 7 | 2021 | 13 | 0.420 |
Why?
|
| Alzheimer Disease | 6 | 2018 | 30 | 0.410 |
Why?
|
| Sulpiride | 3 | 2019 | 7 | 0.410 |
Why?
|
| Drug Chronotherapy | 4 | 2013 | 5 | 0.390 |
Why?
|
| Disease Models, Animal | 2 | 2022 | 45 | 0.390 |
Why?
|
| Metal Nanoparticles | 3 | 2023 | 25 | 0.390 |
Why?
|
| Microinjections | 3 | 2017 | 9 | 0.380 |
Why?
|
| Biological Transport | 4 | 2023 | 11 | 0.380 |
Why?
|
| Blood Platelets | 3 | 2021 | 30 | 0.380 |
Why?
|
| Organic Chemistry Phenomena | 1 | 2011 | 2 | 0.380 |
Why?
|
| Administration, Cutaneous | 9 | 2018 | 31 | 0.380 |
Why?
|
| Diclofenac | 5 | 2016 | 10 | 0.370 |
Why?
|
| Cell Proliferation | 9 | 2022 | 43 | 0.370 |
Why?
|
| Light | 2 | 2021 | 11 | 0.370 |
Why?
|
| Tensile Strength | 7 | 2019 | 13 | 0.370 |
Why?
|
| Inflammation | 6 | 2017 | 103 | 0.360 |
Why?
|
| Eucalyptus | 1 | 2010 | 1 | 0.360 |
Why?
|
| Artemisia | 1 | 2010 | 1 | 0.360 |
Why?
|
| Melaleuca | 1 | 2010 | 1 | 0.360 |
Why?
|
| Biomimetic Materials | 3 | 2020 | 7 | 0.360 |
Why?
|
| Water | 4 | 2022 | 22 | 0.360 |
Why?
|
| Bone Regeneration | 2 | 2023 | 5 | 0.360 |
Why?
|
| Vitreous Body | 1 | 2010 | 2 | 0.350 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2010 | 2 | 0.350 |
Why?
|
| Amyotrophic Lateral Sclerosis | 3 | 2018 | 14 | 0.350 |
Why?
|
| Absorbable Implants | 3 | 2018 | 8 | 0.350 |
Why?
|
| Insulin | 4 | 2017 | 72 | 0.350 |
Why?
|
| Gastric Mucosa | 4 | 2016 | 9 | 0.340 |
Why?
|
| Dopamine Agents | 4 | 2014 | 11 | 0.340 |
Why?
|
| Spinal Cord Injuries | 3 | 2015 | 18 | 0.340 |
Why?
|
| Materials Testing | 8 | 2019 | 16 | 0.340 |
Why?
|
| X-Ray Diffraction | 5 | 2021 | 14 | 0.340 |
Why?
|
| Ligands | 7 | 2018 | 33 | 0.340 |
Why?
|
| Ophthalmic Solutions | 3 | 2016 | 9 | 0.330 |
Why?
|
| Skin Absorption | 4 | 2017 | 8 | 0.330 |
Why?
|
| Antipsychotic Agents | 3 | 2015 | 10 | 0.330 |
Why?
|
| Models, Biological | 7 | 2015 | 77 | 0.320 |
Why?
|
| Nylons | 4 | 2014 | 7 | 0.320 |
Why?
|
| Oligopeptides | 2 | 2023 | 16 | 0.320 |
Why?
|
| Viscosity | 7 | 2015 | 14 | 0.320 |
Why?
|
| Eye | 4 | 2014 | 13 | 0.320 |
Why?
|
| Permeability | 8 | 2017 | 17 | 0.320 |
Why?
|
| Precision Medicine | 2 | 2022 | 9 | 0.310 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2013 | 39 | 0.310 |
Why?
|
| Needles | 4 | 2018 | 12 | 0.310 |
Why?
|
| Skin | 6 | 2023 | 38 | 0.310 |
Why?
|
| Methacrylates | 4 | 2018 | 14 | 0.310 |
Why?
|
| Glycosides | 1 | 2008 | 1 | 0.310 |
Why?
|
| Combinatorial Chemistry Techniques | 1 | 2008 | 1 | 0.310 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2015 | 17 | 0.310 |
Why?
|
| Biopolymers | 3 | 2021 | 4 | 0.300 |
Why?
|
| Polyglactin 910 | 1 | 2007 | 2 | 0.300 |
Why?
|
| Stroke | 2 | 2019 | 59 | 0.300 |
Why?
|
| Drug Implants | 4 | 2016 | 21 | 0.290 |
Why?
|
| Lactobacillus acidophilus | 3 | 2016 | 6 | 0.290 |
Why?
|
| Rats, Wistar | 2 | 2024 | 13 | 0.290 |
Why?
|
| Equipment Design | 4 | 2018 | 27 | 0.290 |
Why?
|
| Calorimetry, Differential Scanning | 9 | 2018 | 20 | 0.280 |
Why?
|
| Brain Diseases | 2 | 2022 | 24 | 0.280 |
Why?
|
| Nanocomposites | 2 | 2017 | 6 | 0.280 |
Why?
|
| Chemical Precipitation | 2 | 2017 | 4 | 0.280 |
Why?
|
| Cyclodextrins | 2 | 2017 | 3 | 0.280 |
Why?
|
| Arthritis | 2 | 2017 | 6 | 0.280 |
Why?
|
| Cholecalciferol | 2 | 2017 | 8 | 0.270 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 137 | 0.270 |
Why?
|
| Fluorouracil | 2 | 2023 | 19 | 0.270 |
Why?
|
| Axons | 3 | 2021 | 7 | 0.270 |
Why?
|
| Intestines | 3 | 2015 | 7 | 0.270 |
Why?
|
| Skin Neoplasms | 2 | 2024 | 12 | 0.260 |
Why?
|
| Bone and Bones | 2 | 2024 | 38 | 0.260 |
Why?
|
| Galantamine | 2 | 2018 | 6 | 0.260 |
Why?
|
| Microspheres | 3 | 2011 | 8 | 0.260 |
Why?
|
| Central Nervous System Agents | 2 | 2016 | 8 | 0.260 |
Why?
|
| In Vitro Techniques | 6 | 2015 | 54 | 0.250 |
Why?
|
| HIV-1 | 4 | 2018 | 1239 | 0.250 |
Why?
|
| Interferon-beta | 2 | 2017 | 7 | 0.250 |
Why?
|
| Cell Survival | 3 | 2020 | 45 | 0.250 |
Why?
|
| Iridoids | 3 | 2021 | 7 | 0.250 |
Why?
|
| Computational Biology | 2 | 2019 | 43 | 0.250 |
Why?
|
| Molecular Structure | 7 | 2022 | 31 | 0.250 |
Why?
|
| Ciprofloxacin | 3 | 2013 | 11 | 0.250 |
Why?
|
| Male | 9 | 2024 | 6489 | 0.250 |
Why?
|
| Adhesiveness | 10 | 2015 | 18 | 0.250 |
Why?
|
| Capsules | 2 | 2023 | 4 | 0.250 |
Why?
|
| Phase Transition | 3 | 2010 | 3 | 0.250 |
Why?
|
| Vitamins | 3 | 2017 | 23 | 0.250 |
Why?
|
| Tenofovir | 2 | 2024 | 158 | 0.240 |
Why?
|
| Amyloid beta-Peptides | 4 | 2018 | 22 | 0.240 |
Why?
|
| Mucins | 2 | 2016 | 5 | 0.240 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2015 | 32 | 0.240 |
Why?
|
| Molecular Dynamics Simulation | 3 | 2020 | 25 | 0.240 |
Why?
|
| Thermodynamics | 6 | 2016 | 19 | 0.230 |
Why?
|
| Aerosols | 1 | 2024 | 7 | 0.230 |
Why?
|
| Administration, Inhalation | 1 | 2024 | 5 | 0.230 |
Why?
|
| Melanoma | 1 | 2024 | 8 | 0.230 |
Why?
|
| Tissue Adhesives | 3 | 2014 | 5 | 0.230 |
Why?
|
| Magnesium Compounds | 1 | 2024 | 1 | 0.230 |
Why?
|
| Oxidation-Reduction | 4 | 2020 | 24 | 0.230 |
Why?
|
| Stomach | 2 | 2015 | 6 | 0.220 |
Why?
|
| Genitalia, Female | 1 | 2024 | 17 | 0.220 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 5 | 2016 | 10 | 0.220 |
Why?
|
| Microscopy, Electron, Transmission | 5 | 2018 | 18 | 0.220 |
Why?
|
| Biosensing Techniques | 2 | 2014 | 6 | 0.220 |
Why?
|
| NIH 3T3 Cells | 2 | 2020 | 7 | 0.220 |
Why?
|
| Chelating Agents | 3 | 2013 | 11 | 0.220 |
Why?
|
| Paclitaxel | 1 | 2023 | 5 | 0.220 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 14 | 0.220 |
Why?
|
| Endothelial Cells | 1 | 2023 | 14 | 0.220 |
Why?
|
| Antigen Presentation | 1 | 2023 | 6 | 0.220 |
Why?
|
| Antigens | 1 | 2023 | 11 | 0.220 |
Why?
|
| Intestinal Absorption | 4 | 2019 | 10 | 0.220 |
Why?
|
| Osteogenesis | 1 | 2023 | 3 | 0.220 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2023 | 3 | 0.220 |
Why?
|
| Injections | 2 | 2021 | 30 | 0.220 |
Why?
|
| Immunologic Factors | 1 | 2023 | 9 | 0.210 |
Why?
|
| Estradiol | 1 | 2023 | 18 | 0.210 |
Why?
|
| Adjuvants, Immunologic | 1 | 2023 | 21 | 0.210 |
Why?
|
| Mannose | 1 | 2023 | 5 | 0.210 |
Why?
|
| Macrophages | 1 | 2023 | 15 | 0.210 |
Why?
|
| Organic Chemicals | 1 | 2022 | 3 | 0.210 |
Why?
|
| Drug Stability | 4 | 2017 | 13 | 0.200 |
Why?
|
| Ferrous Compounds | 1 | 2022 | 4 | 0.200 |
Why?
|
| Diphosphonates | 1 | 2022 | 4 | 0.200 |
Why?
|
| Anticonvulsants | 2 | 2014 | 13 | 0.200 |
Why?
|
| Pharmacists | 1 | 2021 | 4 | 0.200 |
Why?
|
| Professional Competence | 1 | 2021 | 5 | 0.200 |
Why?
|
| Guided Tissue Regeneration | 1 | 2021 | 2 | 0.200 |
Why?
|
| Cues | 1 | 2021 | 3 | 0.200 |
Why?
|
| Brain Ischemia | 2 | 2019 | 9 | 0.190 |
Why?
|
| Administration, Topical | 5 | 2016 | 12 | 0.190 |
Why?
|
| Biotechnology | 1 | 2021 | 4 | 0.190 |
Why?
|
| Anti-Retroviral Agents | 1 | 2006 | 542 | 0.190 |
Why?
|
| Prolamins | 1 | 2021 | 3 | 0.190 |
Why?
|
| Azo Compounds | 1 | 2021 | 6 | 0.190 |
Why?
|
| Phototherapy | 1 | 2021 | 6 | 0.190 |
Why?
|
| Diagnostic Imaging | 3 | 2020 | 9 | 0.190 |
Why?
|
| Antihypertensive Agents | 2 | 2014 | 61 | 0.190 |
Why?
|
| Carboxymethylcellulose Sodium | 4 | 2023 | 8 | 0.180 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 1 | 2020 | 2 | 0.180 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2020 | 6 | 0.180 |
Why?
|
| Cell Shape | 1 | 2020 | 3 | 0.180 |
Why?
|
| Liver | 2 | 2018 | 74 | 0.180 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2020 | 19 | 0.180 |
Why?
|
| Fluorescent Dyes | 2 | 2017 | 13 | 0.180 |
Why?
|
| Glucose Oxidase | 1 | 2020 | 3 | 0.180 |
Why?
|
| Hydrogen Peroxide | 1 | 2020 | 11 | 0.180 |
Why?
|
| Calcium Compounds | 2 | 2019 | 4 | 0.170 |
Why?
|
| Silicates | 2 | 2019 | 4 | 0.170 |
Why?
|
| Gold | 1 | 2020 | 37 | 0.170 |
Why?
|
| Quantum Dots | 1 | 2020 | 1 | 0.170 |
Why?
|
| Carbon | 1 | 2020 | 5 | 0.170 |
Why?
|
| Prednisolone | 2 | 2017 | 10 | 0.170 |
Why?
|
| Amoxicillin | 2 | 2016 | 9 | 0.170 |
Why?
|
| Oleic Acid | 1 | 2019 | 2 | 0.170 |
Why?
|
| Magnesium | 1 | 2019 | 6 | 0.170 |
Why?
|
| Biomimetics | 1 | 2019 | 3 | 0.170 |
Why?
|
| Medication Adherence | 1 | 2021 | 137 | 0.170 |
Why?
|
| Endostatins | 1 | 2019 | 2 | 0.170 |
Why?
|
| Hemostasis | 1 | 2019 | 15 | 0.170 |
Why?
|
| Electrochemical Techniques | 3 | 2013 | 9 | 0.170 |
Why?
|
| Folic Acid | 1 | 2019 | 12 | 0.170 |
Why?
|
| Elastic Modulus | 6 | 2018 | 12 | 0.170 |
Why?
|
| PC12 Cells | 5 | 2019 | 16 | 0.170 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2019 | 9 | 0.170 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 220 | 0.160 |
Why?
|
| Root Canal Filling Materials | 1 | 2019 | 2 | 0.160 |
Why?
|
| Root Canal Irrigants | 1 | 2019 | 2 | 0.160 |
Why?
|
| Ruthenium Compounds | 1 | 2019 | 3 | 0.160 |
Why?
|
| Dopamine Antagonists | 1 | 2019 | 3 | 0.160 |
Why?
|
| Dental Caries | 1 | 2019 | 10 | 0.160 |
Why?
|
| Glioblastoma | 1 | 2019 | 3 | 0.160 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 6 | 0.160 |
Why?
|
| Ethylene Glycols | 2 | 2016 | 4 | 0.160 |
Why?
|
| Elasticity | 2 | 2009 | 6 | 0.160 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2021 | 468 | 0.160 |
Why?
|
| Antineoplastic Protocols | 1 | 2018 | 4 | 0.160 |
Why?
|
| Ink | 1 | 2018 | 2 | 0.160 |
Why?
|
| Carcinoma | 1 | 2018 | 9 | 0.160 |
Why?
|
| Ovalbumin | 2 | 2016 | 5 | 0.160 |
Why?
|
| Crystallization | 3 | 2016 | 8 | 0.160 |
Why?
|
| Economics, Pharmaceutical | 1 | 2018 | 3 | 0.160 |
Why?
|
| Benzoxazines | 2 | 2018 | 119 | 0.150 |
Why?
|
| Dexamethasone | 1 | 2018 | 13 | 0.150 |
Why?
|
| Acrylamide | 1 | 2018 | 2 | 0.150 |
Why?
|
| Cholinergic Antagonists | 2 | 2009 | 5 | 0.150 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 2016 | 16 | 0.150 |
Why?
|
| Glycosaminoglycans | 1 | 2018 | 2 | 0.150 |
Why?
|
| Galactans | 2 | 2015 | 6 | 0.150 |
Why?
|
| Mannans | 2 | 2015 | 6 | 0.150 |
Why?
|
| Plant Gums | 2 | 2015 | 6 | 0.150 |
Why?
|
| Amides | 1 | 2018 | 8 | 0.150 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 128 | 0.150 |
Why?
|
| Membranes | 2 | 2015 | 3 | 0.150 |
Why?
|
| Apoproteins | 1 | 2018 | 2 | 0.150 |
Why?
|
| Lactoferrin | 1 | 2018 | 2 | 0.150 |
Why?
|
| Epichlorohydrin | 2 | 2016 | 4 | 0.150 |
Why?
|
| Calcitonin | 1 | 2018 | 10 | 0.150 |
Why?
|
| Pregnancy | 1 | 2024 | 1815 | 0.150 |
Why?
|
| Pentetic Acid | 1 | 2018 | 4 | 0.150 |
Why?
|
| Amantadine | 1 | 2018 | 6 | 0.150 |
Why?
|
| Sewage | 1 | 2017 | 2 | 0.150 |
Why?
|
| Iron | 1 | 2018 | 32 | 0.150 |
Why?
|
| Metals | 1 | 2017 | 6 | 0.150 |
Why?
|
| Molecular Imaging | 1 | 2017 | 3 | 0.150 |
Why?
|
| alpha-Tocopherol | 1 | 2017 | 2 | 0.150 |
Why?
|
| Ascorbic Acid | 1 | 2017 | 12 | 0.150 |
Why?
|
| Aminosalicylic Acid | 1 | 2017 | 2 | 0.150 |
Why?
|
| Acyclovir | 1 | 2017 | 11 | 0.140 |
Why?
|
| Hepatitis B, Chronic | 1 | 2018 | 44 | 0.140 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2017 | 2 | 0.140 |
Why?
|
| Humic Substances | 1 | 2017 | 2 | 0.140 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2022 | 10 | 0.140 |
Why?
|
| Erythropoietin | 1 | 2017 | 8 | 0.140 |
Why?
|
| Stress, Mechanical | 3 | 2018 | 16 | 0.140 |
Why?
|
| Foscarnet | 2 | 2007 | 4 | 0.140 |
Why?
|
| Drug Evaluation, Preclinical | 4 | 2014 | 11 | 0.140 |
Why?
|
| Analgesia | 1 | 2017 | 8 | 0.140 |
Why?
|
| Fractures, Bone | 1 | 2017 | 21 | 0.140 |
Why?
|
| Gelatin | 1 | 2016 | 2 | 0.140 |
Why?
|
| Flavonoids | 2 | 2016 | 7 | 0.140 |
Why?
|
| Models, Theoretical | 5 | 2019 | 78 | 0.140 |
Why?
|
| Colon | 2 | 2015 | 8 | 0.140 |
Why?
|
| Calcium Chloride | 2 | 2019 | 4 | 0.140 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2016 | 2 | 0.140 |
Why?
|
| Antioxidants | 3 | 2018 | 25 | 0.140 |
Why?
|
| Central Nervous System Diseases | 1 | 2016 | 6 | 0.130 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 10 | 0.130 |
Why?
|
| Felodipine | 1 | 2016 | 2 | 0.130 |
Why?
|
| Calcium Phosphates | 1 | 2016 | 3 | 0.130 |
Why?
|
| Diffusion | 4 | 2010 | 5 | 0.130 |
Why?
|
| Spectrum Analysis | 2 | 2018 | 8 | 0.130 |
Why?
|
| Equipment and Supplies | 1 | 2016 | 3 | 0.130 |
Why?
|
| Drug Industry | 1 | 2016 | 4 | 0.130 |
Why?
|
| Carmustine | 1 | 2016 | 3 | 0.130 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2016 | 4 | 0.130 |
Why?
|
| Esters | 1 | 2016 | 1 | 0.130 |
Why?
|
| Cornea | 1 | 2016 | 2 | 0.130 |
Why?
|
| Time Factors | 3 | 2019 | 503 | 0.130 |
Why?
|
| Hepatitis B virus | 1 | 2018 | 155 | 0.130 |
Why?
|
| Poloxamer | 3 | 2023 | 7 | 0.130 |
Why?
|
| Mental Disorders | 1 | 2016 | 40 | 0.130 |
Why?
|
| Schizophrenia | 1 | 2015 | 4 | 0.130 |
Why?
|
| Emulsions | 2 | 2016 | 5 | 0.130 |
Why?
|
| Beer | 1 | 2015 | 3 | 0.130 |
Why?
|
| Nitrosamines | 1 | 2015 | 3 | 0.130 |
Why?
|
| Aminocaproic Acid | 1 | 2015 | 2 | 0.130 |
Why?
|
| Lipase | 1 | 2015 | 3 | 0.130 |
Why?
|
| Bile Acids and Salts | 1 | 2015 | 3 | 0.130 |
Why?
|
| Drug Resistance | 1 | 2015 | 35 | 0.130 |
Why?
|
| AIDS Dementia Complex | 1 | 2015 | 29 | 0.130 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 26 | 0.130 |
Why?
|
| Microwaves | 1 | 2015 | 3 | 0.130 |
Why?
|
| Hot Temperature | 4 | 2018 | 26 | 0.120 |
Why?
|
| Polystyrenes | 2 | 2015 | 4 | 0.120 |
Why?
|
| Polyphosphates | 4 | 2019 | 10 | 0.120 |
Why?
|
| Menthol | 1 | 2014 | 2 | 0.120 |
Why?
|
| Sulfamethoxazole | 1 | 2014 | 2 | 0.120 |
Why?
|
| Molecular Docking Simulation | 4 | 2016 | 36 | 0.120 |
Why?
|
| Calpain | 1 | 2014 | 2 | 0.120 |
Why?
|
| Polyphenols | 1 | 2014 | 3 | 0.120 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 10 | 0.120 |
Why?
|
| Structure-Activity Relationship | 3 | 2022 | 27 | 0.120 |
Why?
|
| tau Proteins | 2 | 2018 | 7 | 0.120 |
Why?
|
| Cells, Cultured | 3 | 2022 | 79 | 0.120 |
Why?
|
| Models, Statistical | 3 | 2013 | 53 | 0.120 |
Why?
|
| Algorithms | 3 | 2014 | 105 | 0.120 |
Why?
|
| Wounds and Injuries | 1 | 2014 | 26 | 0.120 |
Why?
|
| Skin Physiological Phenomena | 1 | 2014 | 5 | 0.120 |
Why?
|
| Carbamazepine | 1 | 2014 | 1 | 0.120 |
Why?
|
| Timolol | 1 | 2014 | 3 | 0.120 |
Why?
|
| Quercetin | 1 | 2014 | 3 | 0.110 |
Why?
|
| Spectrophotometry, Ultraviolet | 2 | 2013 | 6 | 0.110 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2013 | 3 | 0.110 |
Why?
|
| Analgesics | 1 | 2013 | 4 | 0.110 |
Why?
|
| Amitriptyline | 2 | 2013 | 3 | 0.110 |
Why?
|
| Antidepressive Agents, Tricyclic | 2 | 2013 | 3 | 0.110 |
Why?
|
| Neurites | 1 | 2013 | 1 | 0.110 |
Why?
|
| Pain Management | 1 | 2013 | 12 | 0.110 |
Why?
|
| Hardness | 3 | 2013 | 7 | 0.110 |
Why?
|
| Periodontal Diseases | 1 | 2013 | 2 | 0.110 |
Why?
|
| Analysis of Variance | 1 | 2013 | 64 | 0.110 |
Why?
|
| Eye, Artificial | 1 | 2013 | 3 | 0.110 |
Why?
|
| Carbohydrates | 1 | 2013 | 5 | 0.110 |
Why?
|
| Anterior Eye Segment | 1 | 2013 | 3 | 0.110 |
Why?
|
| Multiple Sclerosis | 1 | 2013 | 4 | 0.110 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2013 | 2 | 0.110 |
Why?
|
| Ergocalciferols | 1 | 2013 | 3 | 0.110 |
Why?
|
| Mucous Membrane | 1 | 2013 | 12 | 0.110 |
Why?
|
| Edetic Acid | 1 | 2013 | 8 | 0.110 |
Why?
|
| Circadian Rhythm | 2 | 2010 | 31 | 0.110 |
Why?
|
| Dental Materials | 1 | 2013 | 2 | 0.110 |
Why?
|
| Genetic Therapy | 2 | 2020 | 35 | 0.110 |
Why?
|
| Iron Chelating Agents | 2 | 2018 | 7 | 0.110 |
Why?
|
| Nootropic Agents | 1 | 2013 | 4 | 0.110 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2013 | 6 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2013 | 42 | 0.110 |
Why?
|
| Mesalamine | 1 | 2012 | 2 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2013 | 10 | 0.110 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2012 | 3 | 0.110 |
Why?
|
| Caco-2 Cells | 3 | 2019 | 10 | 0.100 |
Why?
|
| Nanocapsules | 2 | 2010 | 3 | 0.100 |
Why?
|
| Polyethyleneimine | 3 | 2019 | 8 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 112 | 0.100 |
Why?
|
| Sterilization | 1 | 2012 | 2 | 0.100 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2012 | 2 | 0.100 |
Why?
|
| Intestinal Mucosa | 3 | 2016 | 9 | 0.100 |
Why?
|
| Hexoses | 1 | 2011 | 2 | 0.100 |
Why?
|
| Molecular Conformation | 4 | 2013 | 14 | 0.090 |
Why?
|
| Prodrugs | 1 | 2011 | 10 | 0.090 |
Why?
|
| Powders | 3 | 2017 | 7 | 0.090 |
Why?
|
| Diphenhydramine | 1 | 2011 | 2 | 0.090 |
Why?
|
| Anti-Allergic Agents | 1 | 2011 | 2 | 0.090 |
Why?
|
| Blood Circulation Time | 1 | 2010 | 1 | 0.090 |
Why?
|
| Glucose | 3 | 2022 | 45 | 0.090 |
Why?
|
| Blood-Retinal Barrier | 1 | 2010 | 2 | 0.090 |
Why?
|
| Blood-Aqueous Barrier | 1 | 2010 | 2 | 0.090 |
Why?
|
| Cyclosporine | 1 | 2010 | 4 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 3 | 0.090 |
Why?
|
| Silver | 2 | 2023 | 15 | 0.090 |
Why?
|
| Colorimetry | 1 | 2010 | 1 | 0.090 |
Why?
|
| Electrophoresis, Capillary | 1 | 2010 | 1 | 0.090 |
Why?
|
| Cytosol | 1 | 2010 | 9 | 0.090 |
Why?
|
| Blood Glucose | 3 | 2017 | 106 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 235 | 0.090 |
Why?
|
| Pharmacokinetics | 1 | 2009 | 1 | 0.080 |
Why?
|
| Frontal Lobe | 1 | 2009 | 3 | 0.080 |
Why?
|
| Dopamine | 1 | 2009 | 7 | 0.080 |
Why?
|
| Biometry | 1 | 2009 | 5 | 0.080 |
Why?
|
| Freeze Drying | 3 | 2015 | 7 | 0.080 |
Why?
|
| alpha-Synuclein | 1 | 2009 | 3 | 0.080 |
Why?
|
| Huntingtin Protein | 1 | 2009 | 6 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 1 | 2009 | 18 | 0.080 |
Why?
|
| Mice, Nude | 2 | 2019 | 12 | 0.080 |
Why?
|
| Binding Sites | 2 | 2020 | 43 | 0.080 |
Why?
|
| Protein Binding | 2 | 2020 | 62 | 0.080 |
Why?
|
| Huntington Disease | 1 | 2009 | 21 | 0.080 |
Why?
|
| Reactive Oxygen Species | 2 | 2022 | 23 | 0.080 |
Why?
|
| Ethanolamines | 1 | 2008 | 5 | 0.080 |
Why?
|
| Membranes, Artificial | 1 | 2008 | 6 | 0.080 |
Why?
|
| Dosage Forms | 3 | 2015 | 8 | 0.080 |
Why?
|
| Propranolol | 1 | 2008 | 2 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2022 | 124 | 0.080 |
Why?
|
| Administration, Intranasal | 2 | 2019 | 8 | 0.070 |
Why?
|
| Endocytosis | 2 | 2019 | 6 | 0.070 |
Why?
|
| Microscopy, Atomic Force | 1 | 2007 | 1 | 0.070 |
Why?
|
| Hydrolysis | 1 | 2007 | 3 | 0.070 |
Why?
|
| Factor Analysis, Statistical | 1 | 2007 | 9 | 0.070 |
Why?
|
| Area Under Curve | 1 | 2007 | 19 | 0.070 |
Why?
|
| Injections, Subcutaneous | 1 | 2007 | 22 | 0.070 |
Why?
|
| Drug Synergism | 2 | 2020 | 20 | 0.070 |
Why?
|
| Half-Life | 1 | 2007 | 21 | 0.070 |
Why?
|
| Globus Pallidus | 1 | 2007 | 1 | 0.070 |
Why?
|
| Fetal Tissue Transplantation | 1 | 2007 | 1 | 0.070 |
Why?
|
| Brain Tissue Transplantation | 1 | 2007 | 1 | 0.070 |
Why?
|
| Dopamine Agonists | 1 | 2007 | 1 | 0.070 |
Why?
|
| Deep Brain Stimulation | 1 | 2007 | 1 | 0.070 |
Why?
|
| Stem Cell Transplantation | 1 | 2007 | 2 | 0.070 |
Why?
|
| Parkinsonian Disorders | 1 | 2007 | 4 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2007 | 131 | 0.070 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2008 | 101 | 0.070 |
Why?
|
| Research Design | 1 | 2007 | 123 | 0.070 |
Why?
|
| Developing Countries | 1 | 2009 | 385 | 0.070 |
Why?
|
| Solvents | 3 | 2013 | 15 | 0.070 |
Why?
|
| Thermogravimetry | 2 | 2018 | 4 | 0.070 |
Why?
|
| Hypromellose Derivatives | 2 | 2019 | 5 | 0.070 |
Why?
|
| Alkynes | 2 | 2018 | 113 | 0.070 |
Why?
|
| Cyclopropanes | 2 | 2018 | 119 | 0.070 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2008 | 186 | 0.070 |
Why?
|
| Fluorescein-5-isothiocyanate | 2 | 2016 | 7 | 0.070 |
Why?
|
| Phospholipids | 2 | 2017 | 13 | 0.060 |
Why?
|
| Electric Stimulation | 2 | 2017 | 7 | 0.060 |
Why?
|
| Sus scrofa | 2 | 2016 | 4 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 37 | 0.060 |
Why?
|
| Nerve Growth Factors | 2 | 2015 | 5 | 0.060 |
Why?
|
| Microsomes, Liver | 2 | 2016 | 9 | 0.060 |
Why?
|
| Vaccination | 1 | 2007 | 347 | 0.060 |
Why?
|
| Cytochrome P-450 CYP3A | 2 | 2016 | 11 | 0.060 |
Why?
|
| Zinc | 2 | 2016 | 10 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2015 | 5 | 0.060 |
Why?
|
| Polydioxanone | 1 | 2024 | 2 | 0.060 |
Why?
|
| Carrageenan | 1 | 2024 | 3 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 16 | 0.060 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2016 | 184 | 0.060 |
Why?
|
| Phosphates | 1 | 2024 | 10 | 0.060 |
Why?
|
| Gram-Positive Bacteria | 1 | 2023 | 9 | 0.050 |
Why?
|
| Gram-Negative Bacteria | 1 | 2023 | 15 | 0.050 |
Why?
|
| Molecular Weight | 2 | 2013 | 13 | 0.050 |
Why?
|
| beta Catenin | 1 | 2022 | 5 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 5 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2014 | 139 | 0.050 |
Why?
|
| Apoptosis | 1 | 2022 | 39 | 0.050 |
Why?
|
| Molecular Sequence Data | 2 | 2014 | 263 | 0.050 |
Why?
|
| Africa | 1 | 2023 | 360 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2021 | 23 | 0.050 |
Why?
|
| Pandemics | 1 | 2023 | 280 | 0.050 |
Why?
|
| Tumor Hypoxia | 1 | 2020 | 1 | 0.040 |
Why?
|
| Drug Discovery | 1 | 2020 | 22 | 0.040 |
Why?
|
| Electrodes | 1 | 2020 | 7 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 58 | 0.040 |
Why?
|
| Carbohydrate Conformation | 1 | 2020 | 2 | 0.040 |
Why?
|
| Biomedical Engineering | 1 | 2020 | 2 | 0.040 |
Why?
|
| Mechanical Phenomena | 1 | 2020 | 2 | 0.040 |
Why?
|
| Chemical Phenomena | 1 | 2020 | 6 | 0.040 |
Why?
|
| Acetylcysteine | 1 | 2019 | 4 | 0.040 |
Why?
|
| Aged | 2 | 2016 | 1650 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2019 | 2 | 0.040 |
Why?
|
| Erythrocytes | 1 | 2019 | 11 | 0.040 |
Why?
|
| Necrosis | 1 | 2019 | 7 | 0.040 |
Why?
|
| Leukocytes | 1 | 2019 | 14 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 11 | 0.040 |
Why?
|
| Cell Movement | 1 | 2019 | 11 | 0.040 |
Why?
|
| Calcium Hydroxide | 1 | 2019 | 2 | 0.040 |
Why?
|
| Glass | 1 | 2019 | 2 | 0.040 |
Why?
|
| Gutta-Percha | 1 | 2019 | 2 | 0.040 |
Why?
|
| Root Canal Therapy | 1 | 2019 | 2 | 0.040 |
Why?
|
| Propanolamines | 1 | 2019 | 8 | 0.040 |
Why?
|
| Adsorption | 2 | 2009 | 6 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 20 | 0.040 |
Why?
|
| Body Weight | 1 | 2019 | 110 | 0.040 |
Why?
|
| Acrylamides | 1 | 2018 | 3 | 0.040 |
Why?
|
| Povidone | 1 | 2018 | 3 | 0.040 |
Why?
|
| Methotrexate | 1 | 2018 | 17 | 0.040 |
Why?
|
| Intravitreal Injections | 1 | 2018 | 2 | 0.040 |
Why?
|
| Catalysis | 1 | 2018 | 6 | 0.040 |
Why?
|
| Green Chemistry Technology | 1 | 2018 | 2 | 0.040 |
Why?
|
| Biomechanical Phenomena | 1 | 2018 | 9 | 0.040 |
Why?
|
| Hepatocytes | 1 | 2018 | 19 | 0.040 |
Why?
|
| Biomedical Technology | 1 | 2018 | 10 | 0.040 |
Why?
|
| Glycoconjugates | 1 | 2018 | 2 | 0.040 |
Why?
|
| Protein Conformation, beta-Strand | 1 | 2018 | 3 | 0.040 |
Why?
|
| Protein Conformation, alpha-Helical | 1 | 2018 | 4 | 0.040 |
Why?
|
| Quality of Life | 1 | 2020 | 170 | 0.040 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2018 | 47 | 0.040 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2018 | 13 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2018 | 30 | 0.040 |
Why?
|
| Glycine | 1 | 2017 | 2 | 0.040 |
Why?
|
| Young Adult | 2 | 2016 | 2357 | 0.040 |
Why?
|
| Emtricitabine | 1 | 2018 | 74 | 0.040 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2017 | 2 | 0.040 |
Why?
|
| Molecular Probes | 1 | 2017 | 4 | 0.040 |
Why?
|
| Viscosupplementation | 1 | 2017 | 2 | 0.040 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2017 | 3 | 0.040 |
Why?
|
| Carbon Isotopes | 1 | 2017 | 5 | 0.040 |
Why?
|
| 2-Hydroxypropyl-beta-cyclodextrin | 1 | 2017 | 2 | 0.040 |
Why?
|
| Intestine, Small | 1 | 2017 | 4 | 0.040 |
Why?
|
| Disease Management | 1 | 2018 | 73 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2017 | 8 | 0.040 |
Why?
|
| Surface-Active Agents | 1 | 2017 | 4 | 0.040 |
Why?
|
| Gastric Absorption | 1 | 2017 | 3 | 0.040 |
Why?
|
| Clavicle | 1 | 2017 | 2 | 0.040 |
Why?
|
| Polypropylenes | 1 | 2017 | 2 | 0.040 |
Why?
|
| Fracture Healing | 1 | 2017 | 2 | 0.040 |
Why?
|
| Simvastatin | 1 | 2017 | 9 | 0.040 |
Why?
|
| Serum Albumin, Bovine | 1 | 2016 | 2 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2018 | 303 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 235 | 0.030 |
Why?
|
| Middle Aged | 2 | 2016 | 3425 | 0.030 |
Why?
|
| Microbial Viability | 1 | 2016 | 11 | 0.030 |
Why?
|
| Magnetic Fields | 1 | 2016 | 2 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 4 | 0.030 |
Why?
|
| Acrylates | 1 | 2016 | 2 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2016 | 11 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2016 | 10 | 0.030 |
Why?
|
| Flavanones | 1 | 2016 | 4 | 0.030 |
Why?
|
| Research | 1 | 2016 | 65 | 0.030 |
Why?
|
| South Africa | 2 | 2021 | 7312 | 0.030 |
Why?
|
| Models, Animal | 1 | 2016 | 3 | 0.030 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 2015 | 2 | 0.030 |
Why?
|
| N-Nitrosopyrrolidine | 1 | 2015 | 3 | 0.030 |
Why?
|
| S100 Proteins | 1 | 2015 | 4 | 0.030 |
Why?
|
| Chemotactic Factors | 1 | 2015 | 6 | 0.030 |
Why?
|
| Carcinogens | 1 | 2015 | 6 | 0.030 |
Why?
|
| Ultrasonic Waves | 1 | 2015 | 2 | 0.030 |
Why?
|
| Malonates | 1 | 2015 | 2 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2015 | 43 | 0.030 |
Why?
|
| Vitamin D | 1 | 2015 | 39 | 0.030 |
Why?
|
| Lactose | 1 | 2015 | 2 | 0.030 |
Why?
|
| Tablets, Enteric-Coated | 1 | 2015 | 2 | 0.030 |
Why?
|
| Capillary Permeability | 1 | 2015 | 4 | 0.030 |
Why?
|
| Sulfhydryl Compounds | 1 | 2015 | 1 | 0.030 |
Why?
|
| Polymethyl Methacrylate | 1 | 2014 | 2 | 0.030 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2014 | 2 | 0.030 |
Why?
|
| Disulfides | 1 | 2015 | 6 | 0.030 |
Why?
|
| Cell Engineering | 1 | 2014 | 2 | 0.030 |
Why?
|
| Hardness Tests | 1 | 2014 | 2 | 0.030 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2014 | 5 | 0.030 |
Why?
|
| Chorioallantoic Membrane | 1 | 2014 | 3 | 0.030 |
Why?
|
| Administration, Ophthalmic | 1 | 2014 | 3 | 0.030 |
Why?
|
| Chick Embryo | 1 | 2014 | 8 | 0.030 |
Why?
|
| Phenol | 1 | 2014 | 4 | 0.030 |
Why?
|
| Steroids | 1 | 2014 | 14 | 0.030 |
Why?
|
| Glutathione Transferase | 1 | 2014 | 16 | 0.030 |
Why?
|
| Infusion Pumps | 1 | 2013 | 3 | 0.030 |
Why?
|
| Iontophoresis | 1 | 2013 | 5 | 0.030 |
Why?
|
| Plasticizers | 1 | 2013 | 4 | 0.030 |
Why?
|
| Enterococcus faecalis | 1 | 2013 | 2 | 0.030 |
Why?
|
| Imidazoles | 1 | 2013 | 9 | 0.030 |
Why?
|
| Streptococcus mutans | 1 | 2013 | 6 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2013 | 30 | 0.030 |
Why?
|
| Adult | 2 | 2016 | 5664 | 0.030 |
Why?
|
| Electrolytes | 1 | 2013 | 5 | 0.030 |
Why?
|
| Theophylline | 1 | 2013 | 5 | 0.030 |
Why?
|
| Diltiazem | 1 | 2013 | 2 | 0.030 |
Why?
|
| Methylcellulose | 1 | 2013 | 2 | 0.030 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2013 | 10 | 0.030 |
Why?
|
| Endocrine System | 1 | 2013 | 3 | 0.030 |
Why?
|
| Electric Conductivity | 1 | 2013 | 4 | 0.030 |
Why?
|
| Metabolomics | 1 | 2013 | 5 | 0.030 |
Why?
|
| Feedback | 1 | 2013 | 6 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2013 | 16 | 0.030 |
Why?
|
| Cholesterol | 1 | 2013 | 38 | 0.030 |
Why?
|
| Chromatography, Gel | 1 | 2013 | 4 | 0.030 |
Why?
|
| Software | 1 | 2013 | 36 | 0.030 |
Why?
|
| Hydrochloric Acid | 1 | 2013 | 4 | 0.030 |
Why?
|
| Barium Sulfate | 1 | 2012 | 2 | 0.030 |
Why?
|
| beta-Glucosidase | 1 | 2012 | 2 | 0.030 |
Why?
|
| Polygalacturonase | 1 | 2012 | 2 | 0.030 |
Why?
|
| Life Style | 1 | 2013 | 80 | 0.030 |
Why?
|
| Potassium Compounds | 1 | 2012 | 4 | 0.030 |
Why?
|
| Polymerization | 1 | 2012 | 4 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2013 | 80 | 0.030 |
Why?
|
| Sulfates | 1 | 2012 | 7 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2013 | 100 | 0.030 |
Why?
|
| Health Behavior | 1 | 2013 | 78 | 0.030 |
Why?
|
| Glutaral | 1 | 2012 | 2 | 0.030 |
Why?
|
| Oligosaccharides | 1 | 2012 | 2 | 0.030 |
Why?
|
| Cations | 1 | 2012 | 7 | 0.020 |
Why?
|
| Biomarkers | 1 | 2013 | 322 | 0.020 |
Why?
|
| Metformin | 1 | 2011 | 3 | 0.020 |
Why?
|
| Lecithins | 1 | 2011 | 4 | 0.020 |
Why?
|
| Peptidomimetics | 1 | 2011 | 4 | 0.020 |
Why?
|
| Prostheses and Implants | 1 | 2011 | 5 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2011 | 10 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2011 | 12 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 2011 | 11 | 0.020 |
Why?
|
| Models, Neurological | 1 | 2010 | 4 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2010 | 8 | 0.020 |
Why?
|
| Gastric Emptying | 1 | 2009 | 1 | 0.020 |
Why?
|
| Pharmaceutic Aids | 1 | 2009 | 1 | 0.020 |
Why?
|
| Electrochemistry | 1 | 2009 | 1 | 0.020 |
Why?
|
| Magnetics | 1 | 2009 | 1 | 0.020 |
Why?
|
| Salts | 1 | 2008 | 1 | 0.020 |
Why?
|
| Quality Control | 1 | 2008 | 27 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2010 | 867 | 0.020 |
Why?
|
| Dendrimers | 1 | 2007 | 1 | 0.020 |
Why?
|